tiprankstipranks
Trending News
More News >
aap Implantate AG (DE:AAQ1)
XETRA:AAQ1
Advertisement

aap Implantate (AAQ1) AI Stock Analysis

Compare
2 Followers

Top Page

DE:AAQ1

aap Implantate

(XETRA:AAQ1)

Select Model
Select Model
Select Model
Neutral 47 (OpenAI - 4o)
Rating:47Neutral
Price Target:
€1.50
▼(-7.98% Downside)
The overall stock score is primarily influenced by financial performance challenges, including negative profitability and cash flow issues. Technical analysis indicates a neutral trend, but weak momentum. Valuation is unattractive due to a negative P/E ratio and lack of dividend yield. The absence of earnings call and corporate events data means these factors did not influence the score.

aap Implantate (AAQ1) vs. iShares MSCI Germany ETF (EWG)

aap Implantate Business Overview & Revenue Model

Company Descriptionaap Implantate AG is a medical technology company based in Germany, specializing in the development, manufacture, and marketing of innovative implants and instruments for the orthopedic and trauma surgery sectors. The company focuses on advanced products in the fields of bone healing and trauma care, offering solutions such as bone screws, plates, and innovative fixation technologies aimed at improving patient outcomes and surgical efficiency.
How the Company Makes Moneyaap Implantate generates revenue primarily through the sale of its orthopedic and trauma products to hospitals, clinics, and healthcare providers. Key revenue streams include direct sales of surgical implants and instruments, as well as ongoing supply contracts with healthcare facilities. The company also benefits from partnerships with distributors and collaborators in various regions, enhancing its market reach. Additionally, aap Implantate invests in research and development to continuously innovate its product offerings, which can lead to new revenue opportunities through the introduction of advanced technologies and solutions in the medical device market.

aap Implantate Financial Statement Overview

Summary
aap Implantate shows signs of revenue recovery with an 8.77% growth rate. However, profitability and cash flow remain significant challenges, with negative net profit, EBIT, and EBITDA margins. The balance sheet reflects reduced leverage, but profitability metrics are concerning. Overall, the company needs to address operational inefficiencies and improve cash flow management.
Income Statement
45
Neutral
The company shows a positive revenue growth rate of 8.77% in the latest year, indicating some recovery. However, the net profit margin remains negative, reflecting ongoing profitability challenges. The EBIT and EBITDA margins are also negative, suggesting operational inefficiencies.
Balance Sheet
50
Neutral
The debt-to-equity ratio has improved to 0.16, indicating a reduction in leverage. However, the return on equity remains negative, highlighting profitability issues. The equity ratio is stable, suggesting a reasonable level of financial stability.
Cash Flow
40
Negative
Free cash flow has improved significantly, with a growth rate of 454.96%. However, both operating and free cash flows are negative, indicating liquidity challenges. The ratios of cash flow to net income are not favorable, reflecting cash flow inefficiencies.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue12.20M11.48M11.52M12.17M9.33M
Gross Profit10.67M9.74M10.58M2.32M-2.16M
EBITDA-1.19M-3.43M-1.57M-520.00K-5.40M
Net Income-3.63M-5.13M-2.56M-2.52M-8.94M
Balance Sheet
Total Assets15.84M19.47M20.23M22.95M19.71M
Cash, Cash Equivalents and Short-Term Investments2.46M1.64M236.00K2.11M885.00K
Total Debt1.72M5.29M3.17M5.08M4.36M
Total Liabilities5.38M8.63M7.40M10.18M9.41M
Stockholders Equity10.46M10.85M12.83M12.78M10.29M
Cash Flow
Free Cash Flow-1.45M-3.40M-2.38M-2.99M-4.09M
Operating Cash Flow-1.12M-2.99M-1.89M-2.47M-3.67M
Investing Cash Flow-327.00K-397.00K-469.00K155.00K-140.00K
Financing Cash Flow2.22M4.42M475.00K3.53M1.77M

aap Implantate Technical Analysis

Technical Analysis Sentiment
Positive
Last Price1.63
Price Trends
50DMA
1.64
Negative
100DMA
1.61
Positive
200DMA
1.62
Positive
Market Momentum
MACD
-0.02
Positive
RSI
53.10
Neutral
STOCH
61.98
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:AAQ1, the sentiment is Positive. The current price of 1.63 is above the 20-day moving average (MA) of 1.60, below the 50-day MA of 1.64, and above the 200-day MA of 1.62, indicating a neutral trend. The MACD of -0.02 indicates Positive momentum. The RSI at 53.10 is Neutral, neither overbought nor oversold. The STOCH value of 61.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:AAQ1.

aap Implantate Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
80
Outperform
€46.96M10.913.68%-5.72%-25.19%
67
Neutral
€371.36M23.186.21%1.91%-1.64%22.60%
62
Neutral
€38.01M21.428.42%1.77%-23.48%
47
Neutral
€21.28M-34.28%-0.59%24.03%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
DE:AAQ1
aap Implantate
1.63
-0.12
-6.86%
DE:GME
Geratherm Medical
5.66
2.01
55.20%
DE:M3V
MeVis Medical Solutions
25.80
2.47
10.56%
DE:SBS
STRATEC Biomedical
31.35
-10.00
-24.19%
DE:SBX
SynBiotic SE
2.99
-2.93
-49.49%
DE:E8X
elexxion AG
0.16
-0.16
-50.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 04, 2025